| PL001 |
Brain Tumors/Oncology |
Biomarkers of CAR T cell neurotoxicity: CSF NFL and GFAP in an expansion cohort of pediatric ALL patients |
Juliane Gust |
Seattle |
United States |
| PL002 |
Brain Tumors/Oncology |
Impact of Molecular Subgrouping on Event-Free Survival (EFS): Results of a Children’s Oncology Group (COG) Randomized Trial for Children with Medulloblastoma (MB); COG-ACNS 0331 |
Roger Packer |
Washington |
United States |
| PL003 |
Cognitive/Behavioral Disorders (including Autism) |
Clinical profile of children presenting with functional neurological complaints from a tertiary care center in north India |
Sheffali Gulati |
New Delhi |
India |
| PL004 |
Cognitive/Behavioral Disorders (including Autism) |
Increased Autoimmune Disease in Mothers of Children with Tourette Syndrome and Obsessive-Compulsive Disorder |
Hannah Jones |
Sydney |
Australia |
| PL005 |
Cognitive/Behavioral Disorders (including Autism) |
The relationship between parental stress and mastery, forgiveness, and social support among parents of children with autism in a collectivistic and an individualistic society |
Muhammad Mahajnah |
Hadera |
Israel |
| PL006 |
Critical Care |
Prevalence of Prognostic Discordance for Infants in the Intensive Care Unit |
Sarah Bernstein |
Durham |
United States |
| PL007 |
Demyelinating Disorders |
Interim results from phase 2/3 (ALD-102) and phase 3 (ALD-104) studies of elivaldogene autotemcel (Lenti-D) gene therapy for the treatment of cerebral adrenoleukodystrophy |
Florian Eichler |
Boston |
United States |
| PL008 |
Demyelinating Disorders |
Development of the PedsQL™ Multiple Sclerosis Module items: Focus group and cognitive interviews |
Cristina Gaudioso |
St. Louis |
United States |
| PL009 |
Demyelinating Disorders |
Pediatric MOG antibody-associated syndromes: Description of a novel neuroimaging pattern |
Sylvia Tenembaum |
Buenos Aires |
Argentina |
| PL010 |
Demyelinating Disorders |
Use of disease-modifying therapies in paediatric relapsing remitting multiple sclerosis in the UK: A multi-centre retrospective study |
Omar Abdel Mannan |
London |
United Kingdom |
| PL011 |
Epilepsy |
Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in the Tuberous Sclerosis Complex (TSC) Phase 3 Randomized Controlled Trial (GWPCARE6) |
Charuta Joshi |
Aurora |
United States |
| PL012 |
Epilepsy |
Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5) |
Anup Patel |
Columbus |
United States |
| PL013 |
Epilepsy |
Preventive antiepileptic treatment in infants with Tuberous Sclerosis Complex delays seizure onset and reduces epilepsy incidence and severity in a multi-center, randomized and observational EPISTOP trial |
Katarzyna Kotulska |
Warsaw |
Poland |
| PL014 |
Epilepsy |
Oligonucleotide STK-001 for the treatment of Dravet Syndrome: Cross-species pharmacology and efficacy in a mouse disease model |
Barry Ticho |
Bedford |
United States |
| PL015 |
Epilepsy |
Bridging the Childhood Epilepsy Treatment Gap in Africa (BRIDGE): A Protocol for a Cluster Randomized Clinical Trial of Task-Shifted Epilepsy Care in Three Northern Nigerian Cities |
Edwin Trevathan |
Nashville |
United States |
| PL016 |
Epilepsy |
Diagnostic and prognostic utility of outpatient short term video EEG records in children with seizures: experience from a tertiary care center in north India. |
Prateek Panda |
Rishikesh |
India |
| PL017 |
Epilepsy |
Epilepsy with Myoclonic Atonic Seizures (Doose Syndrome): A Severe Epileptic Encephalopathy with a Positive Outlook? |
Katherine Nickels |
Rochester |
United States |
| PL018 |
Epilepsy |
Electroclinical spectrum of childhood epilepsy secondary to neonatal hypoglycemic brain injury in a low resource setting: A 10 year experience |
Bijoy Patra |
Delhi |
India |
| PL019 |
Epilepsy |
Provider attitudes toward sexual and reproductive healthcare for young women with epilepsy and intellectual disabilities |
Laura Kirkpatrick |
Pittsburgh |
United States |
| PL020 |
Epilepsy |
Role of immunotherapy in children with new onset refractory status epilepticus (NORSE): Hit early and hit hard. |
Harshkumar Patel |
Ahmedabad |
India |
| PL021 |
Epilepsy |
Update on a sponsored no-cost epilepsy gene panel for seizure onset between 2–4 years of age: Results from 682 tests |
Tiffany Pang |
Novato |
United States |
| PL022 |
Epilepsy |
Management practices for West syndrome in South Asia: a survey study and meta-analysis |
Priyanka Madaan |
Chandigarh |
India |
| PL023 |
Epilepsy |
Hemodynamic responses to interictal epileptiforme discharges and clinical prognosis in childhood epilepsy with centrotemporal spikes |
Ana Carolina Coan |
Campinas |
Brazil |
| PL024 |
Epilepsy |
Perspectives on Preferred Practices for Rescue Therapies in Epilepsy: Gaps or Agreement? |
Patricia Shafer |
Wilmington |
United States |
| PL025 |
Epilepsy |
Medically intractable myoclonic epilepsy, intellectual disability, and dysmorphism in a teenage girl caused by a novel variant in NEXMIF |
Isabella Herman |
Houston |
United States |
| PL026 |
Epilepsy |
High dose diazepam treatment for Electrical Status Epilepticus in Sleep (ESES): Is it effective? |
Carolina Gorodetsky |
Toronto |
Ontario |
| PL027 |
Epilepsy |
Thalamocortical Loop Models as an Integrative Framework for Epileptiform Activity. |
Andrew Knox |
Madison |
United States |
| PL028 |
Epilepsy |
Efficacy of Combined Therapy of ACTH plus Vigabatrin compared to ACTH alone for treatment of Infantile Spasm- A Randomized controlled trail |
Samsun Sumi |
Dhaka |
Bangladesh |
| PL029 |
Epilepsy |
Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid |
Nancy McNamara |
Ann Arbor |
United States |
| PL030 |
Epilepsy |
Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open- Label Extension Study |
Joseph Sullivan |
San Francisco |
United States |
| PL031 |
Epilepsy |
Number Needed to Treat (NNT) With Fenfluramine to Achieve a Clinically Meaningful Reduction in Convulsive Seizure Frequency in Patients With Dravet Syndrome |
Joseph Sullivan |
San Francisco |
United States |
| PL032 |
Epilepsy |
POTENTIAL MECHANISMS OF SUDEP IN MOUSE MODEL OF ALTERNATING HEMIPLEGIA OF CHILDHOOD |
Courtney Elliott |
Chapel Hill |
United States |
| PL033 |
Epilepsy |
Improving folate supplementation counseling for adolescent females with epilepsy. |
Sara Fridinger |
Philadelphia |
United States |
| PL034 |
Epilepsy |
Worldwide short course education programmes in paediatric epilepsies – improving knowledge and changing attitudes and practice. |
Alison Gifford |
Dundee |
United Kingdom |
| PL035 |
Epilepsy |
Neuroimaging for Non-Index Seizures in Pediatric Emergency Rooms |
Emma Mazzio |
Denver |
United States |
| PL036 |
Epilepsy |
Decision-Making for Infants with Neurologic Conditions |
Charlotte Gerrity |
Durham |
United States |
| PL037 |
Epilepsy |
The expressions of microRNAs in febrile seizure |
Kursat Carman |
Eskisehir |
Turkey |
| PL038 |
Genetics |
Episodic hemiplegia secondary to channelopathies: clinical spectrum and genotype- phenotype correlations |
Daniel Calame |
Houston |
United States |
| PL039 |
Genetics |
Variability in diagnostic yield of exome sequencing by clinical phenotype: Review of 977 cases from a single center |
Cameron Crockett |
St. Louis |
United States |
| PL040 |
Genetics |
Pediatric 50K (P50K) Heredigene Project: Whole Genome Sequencing Initiative for 50,000 Children: Integrating Genomic Testing and Data with Longitudinal Pediatric Clinical Outcomes and Treatments in an Integrated Healthcare System |
Josh Bonkowsky |
Salt Lake City |
United States |
| PL041 |
Genetics |
Human Genetic Risk and Protective Factors In Congenital Zika Syndrome |
Youssef Kousa |
Washington |
United States |
| PL042 |
Genetics |
Characterization of PTEN-associated cortical malformations and associated clinical phenotype |
Diane Shao |
Boston |
United States |
| PL043 |
Genetics |
Diagnostic yield of genetic testing in infants with congenital hypotonia |
Sonal Sharma |
Kansas City |
United States |
| PL044 |
Infections/Neuroimmunology |
Common autoantigen identified in a cohort of ROHHAD-NET patients, supporting ROHHAD as a novel paraneoplastic neurological disorder |
Caleigh Mandel-Brehm |
San Francisco |
United States |
| PL045 |
Infections/Neuroimmunology |
Think AFM: many patients with acute flaccid myelitis are misdiagnosed |
Leslie Hayes |
Boston |
United States |
| PL046 |
Infections/Neuroimmunology |
Validity of the clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis in Japanese pediatric patients |
Hiroya Nishida |
Tokyo |
Japan |
| PL047 |
Infections/Neuroimmunology |
Comparison of Seizure Type and EEG findings in Autoimmune Encephalitis: A Multicenter Sample |
Annie Hong |
New Hyde Park |
United States |
| PL048 |
Infections/Neuroimmunology |
Clinico-radiological profile of children with acute necrotizing encephalopathy of childhood(ANEC) associated with dengue fever: A case series |
Harshkumar Patel |
Ahmedabad |
India |
| PL049 |
Infections/Neuroimmunology |
GAD65 Antibody Encephalitis presenting as treatment resistant temporal lobe epilepsy and peripheral neuropathy in a pediatric patient |
Maryam Nabavi Nouri |
London |
Ontario |
| PL050 |
Infections/Neuroimmunology |
Acute Encephalitis in the Pediatric Population of Western Pennsylvania |
Meghan Mack |
Pittsburgh |
United States |
| PL051 |
Movement Disorders (including Cerebral Palsy) |
The effect of intrathecal baclofen in dyskinetic cerebral palsy (IDYS trial): a multi-centre, randomised, double-blind, placebo-controlled trial |
Laura Bonouvrie |
Amsterdam |
Netherlands |
| PL052 |
Movement Disorders (including Cerebral Palsy) |
Stereotypies have lower burden of comorbidity compared to tics |
Shannon Dean |
Baltimore |
United States |
| PL053 |
Movement Disorders (including Cerebral Palsy) |
Anxiety symptoms in youth with and without tic disorders |
Jennifer Vermilion |
Rochester |
United States |
| PL054 |
Movement Disorders (including Cerebral Palsy) |
Improved Motor Function in Children With AADC Deficiency Treated with Eladocagene Exuparvovec (PTC-AADC): Interim Findings from a Phase 2 Trial |
Yin-Hsiu Chien |
Taipei City |
Taiwan |
| PL055 |
Movement Disorders (including Cerebral Palsy) |
High-throughput Screen For Small Molecules That Modulate Protein Trafficking In Adaptor Protein Complex 4 (AP-4) Associated Hereditary Spastic Paraplegia |
Darius Ebrahimi-Fakhari |
Boston |
United States |
| PL056 |
Movement Disorders (including Cerebral Palsy) |
Improved Motor Function in Children With AADC Deficiency Treated With Eladocagene Exuparvovec (PTC-AADC): Compassionate Use Study |
Paul Wuh-Liang Hwu |
Taipei City |
Taiwan |
| PL057 |
Neonatal & Fetal Neurology |
Lateralized neonatal EEG response to maternal voice exposure as a predictor of language outcome |
Renee Shellhaas |
Ann Arbor |
United States |
| PL058 |
Neonatal & Fetal Neurology |
Duration of Anti-seizure Medication Treatment and 2-Year Outcome After Acute Symptomatic Neonatal Seizures – a Neonatal Seizure Registry study |
Hannah Glass |
San Francisco |
United States |
| PL059 |
Neonatal & Fetal Neurology |
Short-Term Seizure Recurrence In Neonates With Acute Symptomatic Seizures: Early Vs Late Discontinuation Of Anti-epileptic drugs: A Randomized, Controlled, Non-Inferiority Trial |
Ramesh Konanki |
Hyderabad |
India |
| PL060 |
Neonatal & Fetal Neurology |
Effect of therapeutic hypothermia and pattern of injury on neurodevelopmental outcomes at 1-2 years in a prospective cohort of neonatal encephalopathy |
Ashley Bach |
San Francisco |
United States |
| PL061 |
Neonatal & Fetal Neurology |
Placental abnormalities in a large cohort of neonatal hypoxic-ischemic encephalopathy (HIE) |
Amy Goodman |
San Francisco |
United States |
| PL062 |
Neonatal & Fetal Neurology |
Advanced genetic analysis in fetuses and term neonates with idiopathic cerebral hemorrhage |
Moran Hausman-Kedem |
Tel-Aviv |
Israel |
| PL063 |
Neonatal & Fetal Neurology |
Hyperglycemia in term neonatal encephalopathy associated with increased risk for neonatal seizures |
Carlos Salazar |
Toronto |
Ontario |
| PL064 |
Neurometabolic Disorders |
Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A >4 year update from an ongoing multicenter extension study |
Angela Schulz |
Hamburg |
Germany |
| PL065 |
Neurometabolic Disorders |
Reduction of Rate of Severity Increment in a Cohort of Patients with Niemann-Pick Type C1 (NPC1) Treated Long-Term With Intrathecal Adrabetadex |
Elizabeth Berry-Kravis |
Chicago |
United States |
| PL066 |
Neurometabolic Disorders |
Development of the “Hamburg Best Practice Guidelines for intracerebroventricular (ICV)- enzyme replacement therapy (ERT) in CLN2 Disease” based on 5 years treatment experience in 48 patients |
Christoph Schwering |
Hamburg |
Germany |
| PL067 |
Neurometabolic Disorders |
Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in CLN6- type Batten disease: interim results from the first clinical gene therapy trial |
Emily de los Reyes |
Columbus |
United States |
| PL068 |
Neuromuscular Disorders |
Increased intracranial pressure in pediatric patients with Spinal Muscular Atrophy receiving nusinersen via lumbar puncture |
Stephanie Acord |
Fortworth |
United States |
| PL069 |
Neuromuscular Disorders |
Ataluren delays loss of ambulation and decline in pulmonary function in patients with nmDMD |
Craig McDonald |
Sacramento |
United States |
| PL070 |
Neuromuscular Disorders |
Onasemnogene Abeparvovec-xioi Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 Study Clinical Update (STR1VE-EU) |
Eugenio Mercuri |
Rome |
Italy |
| PL071 |
Neuromuscular Disorders |
Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study |
Boris Kandinov |
Cambridge |
United States |
| PL072 |
Neuromuscular Disorders |
Nusinersen in advanced-stage patients with spinal muscular atrophy type1. |
Katarzyna Kotulska |
Warsaw |
Poland |
| PL073 |
Neuromuscular Disorders |
One-Time Administration of AVXS-101 IT for Spinal Muscular Atrophy: Phase 1/2 Study (STRONG) |
Richard Finkel |
Orlando |
United States |
| PL074 |
Neuromuscular Disorders |
Longer-term Nusinersen Treatment According to Age at First Dose: Results From the SHINE Study in Later-onset Spinal Muscular Atrophy (SMA) |
Basil Darras |
Boston |
United States |
| PL075 |
Neuromuscular Disorders |
Pulmonary function in non-ambulatory patients with nmDMD: Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry and CINRG DNHS matched cohort analysis |
Andrés Nascimento Osorio |
Barcelona |
Spain |
| PL076 |
Neuromuscular Disorders |
Beyond the Muscle: The Expanding Mutational and Phenotypic Spectrum of Disease Due to Mutations in the MICU1 gene (mitochondrial calcium uptake 1) |
Shanawaz Hussain |
Leeds |
United Kingdom |
| PL077 |
Neuromuscular Disorders |
Onasemnogene Abeparvovec-xioi Gene Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update |
Kevin Strauss |
Strasburg |
United States |
| PL078 |
Neuromuscular Disorders |
Nusinersen Effect in Infants Who Initiate Treatment in a Presymptomatic Stage of SMA: NURTURE Results |
Darryl De Vivo |
New York |
United States |
| PL079 |
Neuromuscular Disorders |
Long-Term Follow-Up of Onasemnogene Abeparvovec-xioi Gene Therapy in Spinal Muscular Atrophy Type 1 (SMA1) |
Jerry Mendell |
Columbus |
United States |
| PL080 |
Neuromuscular Disorders |
Georgia state SMA newborn screening (NBS) pilot: clinical outcomes and way forward |
Kathryn Elkins |
Atlanta |
United States |
| PL081 |
Neuromuscular Disorders |
Intravenous (IV) Onasemnogene Abeparvovec-xioi Clinical Development Programs in Spinal Muscular Atrophy (SMA): Integrated Safety Report |
Deepa Chand |
Bannockburn |
United States |
| PL082 |
Neuromuscular Disorders |
Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function |
Erika Finanger |
Portland |
United States |
| PL083 |
Neuromuscular Disorders |
Systemic Gene Transfer with rAAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients with Limb Girdle Muscular Dystrophy Type 2E (LGMD2E) |
Louise Rodino-Klapac |
Cambridge |
United States |
| PL084 |
Neuromuscular Disorders |
Systemic Gene Transfer with rAAVrh74.MHCK7.micro-dystrophin in Patients with Duchenne Muscular Dystrophy |
Jerry Mendell |
Columbus |
United States |
| PL085 |
Neurorehabilitation |
Development and Evaluation of a low-cost working memory intervention kit for cognitive deficits in children with epilepsy: a pilot study |
Aakanksha Anand |
New Delhi |
India |
| PL086 |
Neurorehabilitation |
Efficacy of abobotulinumtoxinA in reducing upper-limb spasticity in children with cerebral palsy: Results from a Phase 3, pivotal study |
Ann Tilton |
New Orleans |
United States |
| PL087 |
Neuroscience |
Dysfunction of D2 dopamine receptor neurons underlies select manic-like behaviors in SHANK3 overexpressing mice |
J. Holder, Jr. |
Houston |
United States |
| PL088 |
Rare Diseases |
The natural history of fatty acid hydroxylase-associated neurodegeneration (FAHN). |
Sunita Venkateswaran |
Ottawa |
Ontario |
| PL089 |
Rare Diseases |
Efficacy and safety of arimoclomol in patients with Niemann Pick Type C: Results from a double-blind, randomised placebo-controlled trial with a novel treatment |
Marc Patterson |
Rochester |
United States |
| PL090 |
Stroke (including other Vascular Disorders) |
Harnessing Multimodal Neuroimaging to Predict Higher-Order Language Outcome Post Neonatal Stroke: An In Vivo Model of Neuroplasticity |
Zahra Emami |
Toronto |
Ontario |
| PL091 |
Stroke (including other Vascular Disorders) |
Robotic sensorimotor assessment of children with perinatal stroke and hemiparesis following intensive motor learning and neuromodulation |
Lauran Cole |
Calgary |
Alberta |
| PL092 |
Stroke (including other Vascular Disorders) |
Regional thalamic dysrhythmia and connectivity abnormalities relate to motor performance in children with perinatal stroke |
Anton Rogachov |
Toronto |
Canada |
| PL093 |
Stroke (including other Vascular Disorders) |
Posterior Choroidal Artery Collaterals Predict Ischemic Event Recurrence and Response to Revascularization Surgery in Childhood Moyamoya |
Matsanga Leyila Kaseka |
Toronto |
Ontario |
| PL094 |
Stroke (including other Vascular Disorders) |
Perinatal infections: an important etiological risk factor for Mineralizing angiopathy in
children |
Mahesh Kamate |
Belagavi |
India |
| PL095 |
Stroke (including other Vascular Disorders) |
Intracranial and extracranial vascular stenosis as risk factors for stroke in sickle cell disease |
Alyssa Schlotman |
Nashville |
United States |
| PL096 |
Stroke (including other Vascular Disorders) |
Cerebral venous sinus thrombosis in infants after surgery for congenital heart disease |
Dana Harrar |
Washington |
United States |
| PL097 |
Teaching of Child Neurology |
Quality Improvement Measures in an Academic Pediatric Neurology Outpatient Practice |
Stephanie Enner |
Queens |
United States |
| PL098 |
Teaching of Child Neurology |
Adoption of Telemedicine within Pediatric Neurology of the MGH Healthcare System before and during the COVID-19 Pandemic |
Albert Misko |
Boston |
United States |
| PL099 |
Translational/Experimental Therapeutics |
Transpher A, an open-label, multicenter, single-dose, dose-escalation, Phase 1/2 Clinical Trial of gene transfer of ABO-102 in Sanfilippo Syndrome type A (Mucopolysaccharidosis IIIA): Safety, tolerability, biopotency and neurocognitive data |
Kevin Flanigan |
Columbus |
United States |
| PL100 |
Trauma |
Cerebral blood flow predicts outcome in children with persistent post-concussion syndrome |
Karen Barlow |
Brisbane |
Australia |
